Axsome Therapeutics (AXSM) Current Assets (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Current Assets data on file, last reported at $611.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 23.57% year-over-year to $611.2 million; the trailing twelve-month figure through Mar 2026 stood at $611.2 million (up 23.57% YoY), and the FY2025 full-year result was $589.0 million, up 21.42% from the prior year.
• Current Assets improved to $611.2 million in Q1 2026, from $589.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $611.2 million in Q1 2026 to a low of $86.8 million in Q1 2022.
• A 5-year average of $424.3 million and a median of $485.1 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets tumbled 47.39% in 2022 and surged 399.81% in 2023, its largest moves.
• Tracing AXSM's Current Assets over 5 years: stood at $245.6 million in 2022, then surged by 105.28% to $504.3 million in 2023, then dropped by 3.81% to $485.1 million in 2024, then grew by 21.42% to $589.0 million in 2025, then advanced by 3.77% to $611.2 million in 2026.
• Business Quant data shows AXSM's Current Assets at $611.2 million in Q1 2026, $589.0 million in Q4 2025, and $565.3 million in Q3 2025.